Elicio Therapeutics Statistics
Total Valuation
ELTX has a market cap or net worth of $92.03 million. The enterprise value is $92.07 million.
Important Dates
The next estimated earnings date is Friday, March 28, 2025, before market open.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ELTX has 10.78 million shares outstanding. The number of shares has increased by 264.13% in one year.
| Current Share Class | 10.78M |
| Shares Outstanding | 10.78M |
| Shares Change (YoY) | +264.13% |
| Shares Change (QoQ) | +20.36% |
| Owned by Insiders (%) | 20.23% |
| Owned by Institutions (%) | 14.27% |
| Float | 7.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | -4.85 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.40
| Current Ratio | 3.40 |
| Quick Ratio | 2.88 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -183.42 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -73.70% |
| Return on Invested Capital (ROIC) | -185.90% |
| Return on Capital Employed (ROCE) | -139.27% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.46M |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +103.33% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +103.33% |
| 50-Day Moving Average | 6.79 |
| 200-Day Moving Average | 5.84 |
| Relative Strength Index (RSI) | 58.77 |
| Average Volume (20 Days) | 59,676 |
Short Selling Information
The latest short interest is 145,788, so 1.35% of the outstanding shares have been sold short.
| Short Interest | 145,788 |
| Short Previous Month | 142,015 |
| Short % of Shares Out | 1.35% |
| Short % of Float | 1.88% |
| Short Ratio (days to cover) | 2.58 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -40.90M |
| Pretax Income | -38.99M |
| Net Income | -46.84M |
| EBITDA | -40.59M |
| EBIT | -40.90M |
| Earnings Per Share (EPS) | -$4.29 |
Full Income StatementBalance Sheet
The company has $26.02 million in cash and $26.05 million in debt, giving a net cash position of -$34,000 or -$0.00 per share.
| Cash & Cash Equivalents | 26.02M |
| Total Debt | 26.05M |
| Net Cash | -34,000 |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | -18.99M |
| Book Value Per Share | -1.76 |
| Working Capital | 21.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$38.22 million and capital expenditures -$42,000, giving a free cash flow of -$38.26 million.
| Operating Cash Flow | -38.22M |
| Capital Expenditures | -42,000 |
| Free Cash Flow | -38.26M |
| FCF Per Share | -$3.55 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |